Placebo To Match Oseltamivir Phosphate — Competitive Intelligence Brief

Placebo To Match Oseltamivir Phosphate (Placebo To Match Oseltamivir Phosphate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase inhibitor. Area: Infectious Disease.

phase 3 Neuraminidase inhibitor Neuraminidase Infectious Disease Small molecule

Target snapshot

Placebo To Match Oseltamivir Phosphate (Placebo To Match Oseltamivir Phosphate) — GlaxoSmithKline. Oseltamivir phosphate is a prodrug that is metabolized into its active form, which is a selective inhibitor of the influenza virus neuraminidase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo To Match Oseltamivir Phosphate TARGET	Placebo To Match Oseltamivir Phosphate	GlaxoSmithKline	phase 3	Neuraminidase inhibitor	Neuraminidase
Oseltamivir phosphate granules	Oseltamivir phosphate granules	China Academy of Chinese Medical Sciences	marketed	Neuraminidase inhibitor	Influenza neuraminidase
ethopabate	ethopabate		marketed		Neuraminidase
zanamivir for inhalation	zanamivir for inhalation	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Tamiflu®	Tamiflu®	Genuine Research Center, Egypt	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
active oseltamivir	active oseltamivir	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase inhibitor class)

1. University of Oxford · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Guangdong Raynovent Biotech Co., Ltd · 2 drugs in this class
4. UMC Utrecht · 2 drugs in this class
5. Genuine Research Center, Egypt · 1 drug in this class
6. The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
7. China Academy of Chinese Medical Sciences · 1 drug in this class
8. Hoffmann-La Roche · 1 drug in this class
9. National Institute for Public Health and the Environment (RIVM) · 1 drug in this class
10. The Affiliated Hospital of Qingdao University · 1 drug in this class